Ovarian Cancer: Frontline Therapy

Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.

EP. 1: Initial Therapy Options for Advanced Ovarian Cancer

April 1st 2021

Dr. Rebecca Previs reviews first line treatment options for patients with advanced ovarian cancer.

EP. 2: Role of Bevacizumab for Initial Therapy in Advanced Ovarian Cancer

April 1st 2021

An expert in gynecologic oncology talks about the role of bevacizumab in the front-line management of advanced ovarian cancer.

EP. 3: Somatic and Germline Testing in Advanced Ovarian Cancer

April 8th 2021

Dr. Rebecca Previs explains the importance of somatic and germline testing in guiding first line treatment selection in women with advanced ovarian cancer.

EP. 4: Front Line Maintenance Options in Advanced Ovarian Cancer

April 8th 2021

An expert oncologist reviews therapeutic options for front line maintenance in advanced ovarian cancer.

EP. 5: Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer

April 15th 2021

Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.

EP. 6: Identifying Patients Appropriate for Front Line Maintenance Therapy in Advanced Ovarian Cancer

April 15th 2021

Dr. Rebecca Previs talks about when first line maintenance therapy is appropriate and which patients should be presented with this option.

EP. 7: Impact of Initial Therapy on Front Line Maintenance Treatment Choice in Advanced Ovarian Cancer

April 22nd 2021

An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.

EP. 8: Emerging Front-Line Maintenance Therapies for Advanced Ovarian Cancer

April 22nd 2021

Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.

EP. 9: Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer

April 22nd 2021

This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.